drugset / Trial / NCT06372821
A Trial Evaluating the Effect of NIO752 on Tau Synthesis Measured by a Process Known as SILK
Phase 1
Recruiting
10 enrolled
University College, London
Alzheimer's Association · collabSigrid Rausing Trust · collabUniversity of Washington · collabWashington University School of Medicine · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
This study will assess if drug (NIO752) reduces production of a protein, tau, by the brain. Normally tau maintains the internal skeleton of nerve cells. In Alzheimer's disease (AD) it builds up in the brain, causing damage. Abnormal tau proteins cling to each other forming 'tangles' inside nerve cells, which interfere with how the nerve cells work, and eventually die. This is what causes the symptoms of dementia. It is thought that NIO752 reduces production of tau.
Timeline
- Start
- 2024-11-18
- Primary completion
- 2026-07
- Completion
- 2026-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NIO752 | Antisense oligonucleotide | — | Intrathecal |